Trademark Overview
On Tuesday, May 14, 2024, a trademark application was filed for CLONALX with the United States Patent and Trademark Office. The USPTO has given the CLONALX trademark a serial number of 98550094. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Tuesday, May 14, 2024. This trademark is owned by Achilles Therapeutics UK Limited. The CLONALX trademark is filed in the Pharmaceutical Products, Treatment & Processing of Materials Services, Computer & Software Products & Electrical & Scientific Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:
Custom manufacture of therapeutic drugs, namely custom manufacture of cell therapies, cancer therapies, neoantigen-specific T cells, TCR-engineered T cells, cancer vaccines and neoantigen vaccines
Bioinformatics software; computer software platforms
Medical and veterinary preparations for therapeutic purposes; preparations for cancer therapy; antibodies; vaccines; personalised cancer vaccines; neoantigen vaccines; preparations for cell therapy; neoantigen-specific T cells; TCR-engineered T cells; preparations for modifying human or animal cells for medical or therapeutic purposes; preparations of blood extracted from humans or animals which have been adapted for medical or therapeutic purposes
Medical services; veterinary services; services in the extraction of human and animal cells from patients; manipulation of human and animal cells for therapeutic purposes; reinsertion of cells into human and animal patients; providing advice and consultancy in the field of medical and veterinary therapies; providing advice and consultancy in the field of cancer therapies and cancer vaccines
Scientific and technological services and research and design relating thereto; industrial analysis and research services; medical and veterinary research services including the manipulation of cells within a laboratory or research facility to enable the cells to be used for medical or therapeutic purposes; scientific research in the development of new cancer therapies, including neoantigen-specific T cells and TCR-engineered T cells; scientific research in human and animal cell therapy; scientific research into vaccines, including personalised cancer vaccines and neoantigen vaccines; scientific research into preparations for manipulating and adapting human and animal cells; consultancy relating to all the aforesaid services